$BMY News Article - U.S. Food and Drug Administration Accepts for Priority Review supplemental Biologics License Application for Reblozyl (luspatercept-aamt) in Adults with Non-Transfusion Dependent (NTD) Beta Thalassemia
https://marketwirenews.com/news-releases/u-s-...05317.html